Search research articles
Contact Us
Filters
Showing results (231-240 of 338) with videos related to
Page
of 34
Sort By:
AIDS (London, England)
|
January 26, 2018
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
Nikki Mulligan, Brookie M Best, Jiajia Wang, et al.
The European Respiratory Journal
|
February 19, 2026
Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis
Ashritha R Chalamalla, Elizabeth Baker, Kevin J Ryan, et al.
AIDS (London, England)
|
April 15, 2015
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients
Cecile D Lahiri, Sijia Tao, Yong Jiang, et al.
AIDS (London, England)
|
May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics
Hardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
Clinical Pharmacology and Therapeutics
|
May 29, 2014
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach
M A Kamal, E P Acosta, D W Kimberlin, et al.
Antimicrobial Agents and Chemotherapy
|
June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
Edward P Acosta, Michelle A Kendall, John G Gerber, et al.
AIDS (London, England)
|
November 21, 2009
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia
Karen M Megazzini, Moses Sinkala, Sten H Vermund, et al.
The Journal of Infectious Diseases
|
July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Journal of Clinical Pharmacology
|
March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age
Matthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
Plos Neglected Tropical Diseases
|
April 16, 2021
Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study
Susannah Colt, Blanca Jarilla, Palmera Baltazar, et al.
Page
of 34
Search research articles
Search
Showing results (231-240 of 338) with videos related to
Sort By:
Page
of 34
AIDS (London, England)
|
January 26, 2018
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
Nikki Mulligan, Brookie M Best, Jiajia Wang, et al.
The European Respiratory Journal
|
February 19, 2026
Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis
Ashritha R Chalamalla, Elizabeth Baker, Kevin J Ryan, et al.
AIDS (London, England)
|
April 15, 2015
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients
Cecile D Lahiri, Sijia Tao, Yong Jiang, et al.
AIDS (London, England)
|
May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics
Hardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
Clinical Pharmacology and Therapeutics
|
May 29, 2014
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach
M A Kamal, E P Acosta, D W Kimberlin, et al.
Antimicrobial Agents and Chemotherapy
|
June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
Edward P Acosta, Michelle A Kendall, John G Gerber, et al.
AIDS (London, England)
|
November 21, 2009
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia
Karen M Megazzini, Moses Sinkala, Sten H Vermund, et al.
The Journal of Infectious Diseases
|
July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Journal of Clinical Pharmacology
|
March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age
Matthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
Plos Neglected Tropical Diseases
|
April 16, 2021
Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study
Susannah Colt, Blanca Jarilla, Palmera Baltazar, et al.
Page
of 34